Joachim N. Nilsson
Stockholm, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
From bench to bedside: the evolving role of iodine in thyroid cancer management.
Journal: Nature reviews. Endocrinology
Published: May 29, 2026
Predicting Radioiodine Therapy Response in Advanced and Recurrent Thyroid Cancer.
Journal: Endocrine-related cancer
Published: May 15, 2026
Fraction-dependent dose dynamics and clinical safety in high-risk neuroblastoma treated with [177Lu]Lu-DOTATATE: results from the LuDO-N trial.
Journal: European journal of nuclear medicine and molecular imaging
Published: April 20, 2026
Feasibility of [89Zr]Zr-Atezolizumab Immuno-PET for PD-L1 Quantification in the Clinical Work-up of Metastatic Triple-Negative Breast Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 18, 2025
Comprehensive Gene Expression Analysis in Papillary Thyroid Carcinoma Reveals a Transcriptional Profile Associated with Reduced Radioiodine Avidity.
Journal: Endocrine pathology
Published: February 11, 2025
Heterogeneous SSTR2 target expression and a novel KIAA1549::BRAF fusion clone in a progressive metastatic lesion following 177Lutetium-DOTATATE molecular radiotherapy in neuroblastoma: a case report.
Journal: Frontiers in oncology
Published: March 28, 2024
Risk of treatment-altering haematological toxicity and its dependence on bone marrow doses in peptide receptor radionuclide therapy.
Journal: EJNMMI research
Published: October 31, 2023
Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up.
Journal: European thyroid journal
Published: May 15, 2023
Primary tumour iodine avidity in relation to uptake in persistent metastatic disease in papillary and poorly differentiated thyroid cancer.
Journal: Endocrine
Published: April 10, 2023
Last Updated: 09/26/2026